In many patients with chronic bronchitis and emphysema right and left ventricular ejection fractions (RVEF and LVEF) are reduced. A study was conducted using multiple gated equilibrium radionuclide ventriculography to compare the effects of oral salbutamol 4 mg and pirbuterol 15 mg on cardiac function in 12 patients with chronic bronchitis (forced expiratory volume in one second 0 86 (SEM 0 12) 1; arterial oxygen pressure 8-2 (SEM 0 5) kPa (61-7 (SEM 3 8) mm Hg)). Different doses of nebulised salbutamol (500 jig and 5 mg) were also compared in nine of the patients. Both oral salbutamol and oral pirbuterol produced significant increases in RVEF and LVEF at 60 and 90 minutes after drug ingestion (p <0 01 in each case). There were no significant differences between salbutamol and pirbuterol in their effects on RVEF and LVEF. Inhaled salbutamol at doses commonly prescribed had no significant effect on RVEF and LVEF after 20 and 60 minutes.
Introduction
Clinical evidence of right ventricular failure is associated with a poor prognosis in patients with chronic bronchitis, and the five year survival rate is frequently quoted as only 30%.1 Such vascular resistance and an improvement in cardiac index.5 7 There is little information about the effect of salbutamol on cardiac function in patients with chronic bronchitis and emphysema. We have compared the effects of oral salbutamol and oral pirbuterol and have also studied the effect of inhaled salbutamol on RVEF and LVEF in these patients.
Methods
We studied 12 patients with severe airflow limitation due to chronic bronchitis and emphysema ( (p<0 01 in each case). There were no significant differences between salbutamol and pirbuterol in their effects on RVEF and LVEF. The increments produced by each drug were not related to the initial ejection fractions (Tukey's corner test for monotonic association"''). Mean heart rate increased from 67 (SEM 2)/min at rest to 86 (3) and 85 (2)/min at 60 and 90 minutes after oral salbutamol. After pirbuterol there was an increase from 75 (4)/min to 92 (4) and 84 (4)/ min at 60 and 90 minutes respectively. There was no significant difference between the drugs in the increases in heart rate produced. Table II shows the effects of inhaled salbutamol on RVEF and LVEF. Overall there was no significant effect with either 500 jig or 5 mg. Nevertheless, the response to 5 mg was variable and there was a trend towards an increase in LVEF, though not in RVEF.
The mean differences between repeated measurements on two occasions for RVEF and LVEF were 0-03 (SEM 0 01) and 0-04 (0 01) respectively. The mean differences between two assessments on different occasions by the same observer of the same equilibrium study were 0 02 (0-003) and 0 01 (0 003) for RVEF and LVEF respectively.
Discussion
Our patients with chronic bronchitis and emphysema with severe airflow limitation had reduced RVEF and LVEF at rest. Similar findings were reported by Macnee and colleagues, who found that RVEF was correlated with arterial oxygen concentration and inversely correlated with carbon dioxide tension. 2 We find, like Xue and colleagues,8 that while RVEF varies considerably in chronic bronchitis, reproducible results are obtained on repeated assessment of individual patients, permitting evaluation of acute therapeutic regimens.
In cardiac failure due to coronary artery disease oral pirbuterol and salbutamol increase cardiac output. The dominant mechanism is a reduction in systemic vascular resistance rather than a direct inotropic effect.5 Our results show a similar improvement in left heart performance in chronic bronchitis after oral P, agonists.
Other studies with invasive techniques have shown a fall in pulmonary artery pressure after oral pirbuterol in patients with chronic bronchitis4 and after oral salbutamol in patients with coronary artery disease.6 Probably the improvement in RVEF seen is mediated mainly by a fall in pulmonary artery pressure and a reduction in pulmonary vascular resistance. We found that both oral salbutamol and pirbuterol produced similar increases in RVEF in patients with chronic bronchitis.
In most patients inhaled salbutamol at doses commonly prescribed produced no effect on RVEF and LVEF. The variable response to the larger dose may reflect variable absorption of the drug by this route.
It has been suggested that because pirbuterol has appreciable inotropic action and vasodilator properties it may improve cardiac function to a greater extent than other P2 agonists.'1 At doses that produce equal peak bronchodilatation we found no difference between pirbuterol and salbutamol in their effects on RVEF and LVEF in patients with chronic hypoxia due to chronic bronchitis and emphysema. The increase in RVEF may not be beneficial because it may be accompanied by redistribution of pulmonary perfusion, which may adversely affect arterial oxygen saturation.3 Further studies are necessary to assess the effects of long term P2 agonists in this group of patients.
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